Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Inclusion Criteria: * Signed informed consent must be obtained prior to participation * Able to complete adequate fundus photographs and retinal images * Diagnosis of type 1 or 2 Diabetes Mellitus (DM) and HbA1c less than or equal to 12% at screening * DM treatment stable for at least 3 months * PDR diagnosis with no previous PRP treatment in the study eye Exclusion Criteria: * Concomitant conditions or ocular disorders in the study eye at Screening or Baseline that could compromise a response to study treatment. * Presence of diabetic macular edema in the study eye * Active infection or inflammation in the study eye * Uncontrolled glaucoma (IOP greater than 25 mmHg) * Intravitreal anti-VEGF treatment within 6 months * Treatment with intraocular corticosteroids * End stage renal disease requiring dialysis or kidney transplant * Uncontrolled blood pressure * Systemic anti-VEGF therapy at any time Other protocol-defined inclusion/exclusion criteria may apply.